Physician profile
Rodney K Bates
NPI 1477596542
$2,243.48
in general payments reported to CMS, 2019-2025
31 companies · $42.47 in 2025
The $42.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $434 · 2021: $537 · 2022: $280 · 2023: $373 · 2024: $116 · 2025: $42.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $387.38 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $326.56 | 2019-2024 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $200.21 | 2019-2022 | |
| Pfizer INC. | $116.23 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $112.74 | 2019-2022 | |
| Glaxosmithkline, LLC. | $110.60 | 2019-2024 | Trelegy Ellipta, Bexsero, Arexvy |
| Amgen INC. | $100.05 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $99.51 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.34 | 2019-2021 | |
| Esperion Therapeutics, INC. | $75.15 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $66.27 | 2019 | |
| Abbott Laboratories | $59.73 | 2021-2022 | |
| Medtronic, INC. | $59.44 | 2021-2023 | Minimed 770g |
| E.R. Squibb & Sons, L.L.C. | $57.87 | 2019-2022 | |
| Astellas Pharma US INC | $49.98 | 2019-2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.30 | 2020-2023 | Gardasil 9, Vaxelis, Vaxneuvance |
| Novo Nordisk INC | $25.16 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.96 | 2021 | |
| Amarin Pharma, INC. | $23.03 | 2019-2021 | |
| Shield Therapeutics INC | $20.89 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $20.68 | 2022 | |
| Biogen, INC. | $18.91 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $15.46 | 2020 | |
| Dexcom, INC. | $14.33 | 2021 | |
| Agile Therapeutics, INC. | $13.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.18 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.01 | 2020 | |
| Sobi, INC | $12.48 | 2019 | |
| Genentech USA, INC. | $11.05 | 2020 | |
| Axsome Therapeutics, INC. | $9.90 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.